BiotechTube

Loncastuximab Tesirine + Rituximab + Gemcitabine + Oxaliplatin

Phase 3Active
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed Diffuse Large B-Cell Lymphoma

Conditions

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

Trial Timeline

Sep 16, 2020 → Jun 30, 2028

NCT ID
NCT04384484

About Loncastuximab Tesirine + Rituximab + Gemcitabine + Oxaliplatin

Loncastuximab Tesirine + Rituximab + Gemcitabine + Oxaliplatin is a phase 3 stage product being developed by ADC Therapeutics for Relapsed Diffuse Large B-Cell Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT04384484. Target conditions include Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04384484Phase 3Active

Competing Products

20 competing products in Relapsed Diffuse Large B-Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
41
agenT-797MiNK TherapeuticsPhase 1
25
VIP152 + BTKiVincerx PharmaPhase 1
25
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
44
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
77
AC220Daiichi SankyoPhase 1
33
Valemetostat TosylateDaiichi SankyoPhase 2
52
LinsitinibAstellas PharmaPhase 2
52
AGS67EAstellas PharmaPhase 1
33
Mitoxantrone Hydrochloride Liposome & EnlonstobartSun PharmaceuticalPhase 1/2
41
LenvatinibEisaiPhase 2
52
TazemetostatEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
Eribulin mesylateEisaiPhase 2
52
ME-401Kyowa KirinPhase 1
33
KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6Kyowa KirinPhase 1
33
MogamulizumabKyowa KirinPhase 2
52
ONO-4685Ono PharmaceuticalPhase 1
33
ONO-4685Ono PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
77

Other Products from ADC Therapeutics

Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/KgPhase 2
44
Loncastuximab tesirine + RituximabPhase 2
44
Loncastuximab Tesirine + RituximabPhase 2
44
Loncastuximab tesirinePhase 2
44
Loncastuximab Tesirine + RituximabPhase 2
44